Shares in Mylan (NSDQ:MYL) remained steady today after the pharmaceutical company missed expectations on Wall Street with its third quarter results.
The Canonsburg, Penn.-based company posted profits of $88.3 million, or 16¢ per share, on sales of $2.99 billion for the 3 months ended Sept. 30, for bottom-line growth of 172% on sales loss of -2% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan misses sales, earnings estimate in Q3 appeared first on MassDevice.